{"nctId":"NCT01539512","briefTitle":"A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)","startDateStruct":{"date":"2012-04"},"conditions":["Chronic Lymphocytic Leukemia"],"count":220,"armGroups":[{"label":"Idelalisib + rituximab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Idelalisib","Drug: Rituximab"]},{"label":"Placebo + rituximab","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Rituximab","Drug: Placebo to match idelalisib"]}],"interventions":[{"name":"Idelalisib","otherNames":["Zydelig®","GS-1101","CAL 101"]},{"name":"Rituximab","otherNames":["Rituxan®"]},{"name":"Placebo to match idelalisib","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion:\n\n* Adult subjects with previously treated recurrent CLL who have measurable lymphadenopathy\n* Require therapy for CLL\n* Have experienced CLL progression \\< 24 months since the completion of the last prior therapy\n* Currently not sufficiently fit to receive cytotoxic therapy because of chemotherapy-induced bone marrow damage or comorbidities.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival","description":"Progression-free survival was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate","description":"Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response.\n\nComplete response was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \\& biopsy.\n\nPartial response was defined as \\>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \\> 100000/μL platelets, \\> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":null},{"groupId":"OG001","value":"14.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Lymph Node Response Rate","description":"Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the SPD of index lymph nodes.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as the interval from randomization to death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response Rate","description":"Complete response rate was defined as the percentage of participants who achieved a complete response.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":65,"n":110},"commonTop":["Fatigue","Cough","Pyrexia","Nausea","Infusion related reaction"]}}}